Meanwhile, the systemic therapy for cutaneous melanoma (CM) has improved recently by immunotherapy (immune checkpoint inhibitors) and targeted therapy; this therapeutic approach inhibits the mitogen-activated protein kinase (MAPK) pathway including BRAF, NRAS, MEK, and KIT. The gene discussed is NRAS; the disease is cutaneous mastocytosis.